LINCARE HOLDINGS INC.



Forward-Looking Statements

Certain statements contained in this presentation constitute forward-looking statements. Such forwardlooking statements are based on management's current expectations and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from those expressed or implied by such forward-looking statements. Such factors include, among others, the following: general economic and business conditions, both nationally, regionally and in the healthcare industry; demographic changes; industry consolidation; regulation and/or regulatory action affecting the Company; the ability to participate in managed care provider arrangements on acceptable terms; changes in Medicare, Medicaid and other third party payor payment policies or reimbursement rates, including those resulting from a shift from traditional reimbursement to managed care plans; liability and other claims asserted against the Company; competitive conditions; technological, pharmaceutical and other improvements that increase the cost of providing, or reduce the demand for, the Company's products and services; shortages of product, equipment or supplies, a breakdown in the distribution process or other factors that may increase the Company's cost of sales; changes in business strategy or development plans; the ability to attract and retain gualified personnel, including the impact on the Company's labor expenses resulting from a shortage of health care professionals; the availability to the Company of borrowed and/or equity capital on favorable terms; the availability of suitable acquisition opportunities and the length of time it takes to accomplish acquisitions; the Company's ability to integrate new businesses with its existing operations and efficient operation of the Company's existing and future operating facilities. Certain additional risks and uncertainties are discussed in the Company's filings with the Securities and Exchange Commission, including the Company's annual report on Form 10-K and guarterly reports on Form 10-Q. Do not rely on any forward-looking statement, as the Company cannot predict or control many of the factors that ultimately may affect its ability to achieve the results estimated. The Company makes no promise to update any forward-looking statement, whether as a result of changes in underlying factors, new information, future events or otherwise.



Largest Provider in a Scale Business

• 1,108 Centers

• Over 800,000 Patients in 48 States and Canada


- 35 Billing / Collections Offices
- 31 Pharmacies

PROFILE

• Local presence drives business while scale drives economics








PROFILE

Our Patients:

PROFILE

550,000 Oxygen 200,000 **Respiratory Medications** 300,000 Sleep Apnea Diabetic 50,000 1,100,000






Revenue Growth:

- Aging Population
 - Medicare population growing <u>and</u> aging
 - Respiratory disease incidence increasing
 - Duration of service continues to increase
- Scale-based market share gains
 - Strong organic growth
 - Tuck-in acquisitions
- \rightarrow 10% CAGR revenue growth



Aging Population



Needed Services: COPD

16 Million People with COPD


EVENUE

m

- 750,000+ Hospital Admissions
- Average Admission Cost \$18,000
- \$40 Billion in Healthcare Costs
- Sharply Rising Incidence (+150% since 1965)




Sleep Apnea Market



REVENUE


Reaching the Undiagnosed

Co-Morbidity Prevalence



REVENUE

Services Duration: Oxygen




Internal Growth

- Face to Face Sales Calls
- Increased Sales Productivity
- Clinical Excellence

REVENUE

- Full Time Respiratory Therapists
- DeNovo Development
 - Market Share Gains






Market Share

REVENUE


	2011 <u>Market Share</u>	Organic <u>Growth</u>	
Locals	43%	3%	
Nationals	29%	0%	
Lincare	28%	6%	



Operating Performance







LINCARE 17

Effective Information Systems

2011 Accounts Receivable Management

- Proprietary, Single Platform
- Accounts Receivable Management
- Cost Control

OPERATING LEVERAGE

• Effective Selling





LINCARE

Financial Highlights

(\$MM)	<u>Q4 2011</u>	<u>Q4 2010</u>
Net Revenues	\$492.2	\$422.1
Net Income	44.6	46.1
EPS (\$/share)	\$0.51	\$0.48




Capitalization

(\$MM)

	<u>12/31/08</u>	<u>12/31/09</u>	<u>12/31/10</u>	<u>12/31/11</u>
Total Assets	\$1,938.8	\$1,877.2	\$2,047.8	\$2,117.7
Cash and Investments	133.1	79.1	204.2	55.0
Total Debt	460.9	484.9	494.9	653.9
Stockholders' Equity	1,028.5	901.9	997.7	885.9
Leverage Ratio (Net Debt / EBITDA)	0.6x	1.1x	0.6x	1.3x

Free Cash Flow



2012 Street Estimates^(*)

Revenue \$2.009 BillionEBITDA \$500 MillionEPS \$2.26 per share

(*) Source: Reuters, February 6, 2012



2012 Priorities

Drive Operating Results Gain Market Share Increase Ancillary Business Invest Cash Flow Effectively



Investment Considerations

- Attractive Growing Market
 - Industry Leader in a Scale Business
 - Non-Discretionary, Recurring Demand
- Financial Flexibility
 - Strong Balance Sheet
 - Low Capital Intensity
 - High, Sustained Free Cash Flow
- Operational Excellence
 - Consistent, High Profitability
 - Efficient National Clinical Sales Force
 - Strong Relationships with Decision Makers

